未登录

M

Matisyahu Shulman

Columbia University

H指数:13

被引数:978

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Thresholds for adjunctive medication usage and probability of initiating injectable naltrexone

阿片类药物辅助治疗的使用阈值和启动注射用纳曲酮的概率

IF5.3

2025-09-170

PRE

Factors associated with receipt of second injection of naltrexone for opioid use disorder: Secondary analysis of 5 clinical trials

与接受纳曲酮第二次注射相关的因素：5项临床试验的二次分析

american journal on addictions

IF0

2025-06-080

PRE

Effects of randomization to buprenorphine or naltrexone for OUD on cannabis use outcomes: A secondary analysis of the X:BOT trial

随机分配丁丙诺啡或纳曲酮治疗OUD对大麻使用结果的影响: X:BOT试验的二次分析

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2025-03-010

PRE

Comparative effectiveness of extended-release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients

缓释纳曲酮和舌下丁丙诺啡治疗医疗补助患者阿片类药物使用障碍的疗效比较

IF5.3

2024-08-052

OA

Association of Baseline Fentanyl Use and Opioid Withdrawal Symptoms During Inpatient Buprenorphine Initiation in a Large Multisite Detoxification Trial

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2024-07-010

PRE

Patient Characteristics of Fentanyl Positive Individuals With Opioid Use Disorder

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2024-07-010

PRE

Patient Characteristics Associated With Retention on XR-NTX in the CTN-0051 Trial

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2024-07-010

PRE

Ethical and Methodological Challenges in Studying Discontinuation of Medications for Opioid Use Disorder

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2024-07-010

PRE

Commentary on Foot et al.: Clinical considerations in addressing comorbid stimulant use in opioid use disorder

IF5.3

2023-10-180

OA

Secondary Analysis of Agreement Between Negative Timeline Follow Back Report and Negative Urine Toxicology in a Large Trial of Individuals with Opioid Use Disorder

JOURNAL OF ADDICTION MEDICINE

IF3.2

2023-05-172

OA

Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2022-10-017

OAAI

Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2022-07-015

OAAI

Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse (vol 131, 108447, 2021)

JOURNAL OF SUBSTANCE ABUSE TREATMENT

IF4

2022-05-011

OAAI

The opioid use disorder core outcomes set (OUD-COS) for treatment research: findings from a Delphi consensus study

IF5.3

2022-04-2514

OA

Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2022-04-012

OAAI

Baseline- and treatment-associated pain in the X:BOT comparative effectiveness study of extended-release naltrexone versus buprenorphine-naloxone for OUD

X中基线和治疗相关的疼痛: 缓释纳曲酮与丁丙诺啡-纳洛酮对OUD的BOT比较效果研究

ADDICTION BIOLOGY

IF2.6

2021-12-072

PREAI

Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse

JOURNAL OF SUBSTANCE ABUSE TREATMENT

IF4

2021-12-0120

OAAI

Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse

IF5.3

2021-10-016

OAAI

Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis

IF5.3

2021-05-212

OAAI

Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure

在医学监督的阿片类药物戒断期间使用美沙酮或丁丙诺啡与缓释可注射纳曲酮诱导失败之间的关联

JOURNAL OF SUBSTANCE ABUSE TREATMENT

IF4

2021-05-019

OAAI